SCHEMBL3010726

SCHEMBL3010726

O=S(=O)(c1cccc(Br)c1)N1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GBA1 P04062 4/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 4/20 0.40
TSHR P16473 3/20 0.40
GAA P10253 2/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
GPR183 P32249 1/20 0.39
MBTD1 Q05BQ5 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
CYP3A4 P08684 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006161 0.93 MEN1 (0.42) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3007251 0.93 MEN1 (0.42) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3008742 0.91 ALDH1A1 (0.46) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3012672 0.90 KMT2A (0.50) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3019392 0.90 ALDH1A1 (0.45) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3012916 0.90 SMN1; SMN2 (0.49) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3005969 0.89 GBA1 (0.44) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3006492 0.89 SMN1; SMN2 (0.46) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3017026 0.88 MEN1 (0.44) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2
SCHEMBL3005390 0.88 SMN1; SMN2 (0.45) MEN1KMT2AGBA1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.